In its latest meeting the CHMP recommended eight medications for approval, 17 medicines for indication extension and concluded reviews of two COVID-19 treatments.
List view / Grid view
Obstructive Sleep Apnea
EU marketing authorisation has been given to Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.
Therapix Biosciences Ltd, have announced that the first subject was enrolled for its Phase IIa, a sponsor-initiated clinical trial for Obstructive Sleep Apnea...